Intelligent anti-aging skin care based on independent research     
Lose wrinkles, keep your bank account!     
 
Skin Care 101
Skin Care Basics
Skin Protection
Skin Biology
Biology of Aging
Ingredient Guide
Skin & Nutrition
Skin Conditions
 
Anti-Aging Treatments
Topical Actives
Wrinkle Fillers
Noninvasive
Invasive
 
Skin Care Smarts
Smart Choices
Best Practices
Find Good Skin Doc
Quick Tips
Freebie Finder
 
Reviews & Research
Product Reviews
Provider Reviews
Skin Care Research
Clinical Trials
 
How-To Infopacks
Skin Rejuvenation
DIY Skin Care
Skin & Nutrition
Eye Skin Care
Longevity In a Pill
 
Community & Misc
Forums
Polls & Surveys
News and Updates
Search
 
   
You are here: Skin Care Research >

Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism.

Author: Batukan C, Muderris II, Ozcelik B, Ozturk A

Author affiliation: Department of Obstetrics and Gynecology, Erciyes University School of Medicine, Kayseri, Turkey.

Publication date & source: 2007.01, Gynecol Endocrinol., 23(1):38-44.

Publication type: Comparative Study; Randomized Controlled Trial

Combined oral contraceptives (COCs) are considered the first-line treatment for women with hirsutism. They diminish androgen release from the ovary and decrease plasma free testosterone levels by increasing sex hormone-binding globulin (SHBG) concentrations. COCs containing cyproterone acetate (CPA) and drospirenone (DRSP) have been proved effective for the treatment of acne and facial hirsutism. This study prospectively compared the clinical and biochemical efficacy of 3 mg DRSP/30 microg ethinyl estradiol (EE) and 2 mg CPA/35 microg EE combinations in a total of 91 patients with hirsutism. Individuals randomly received a cyclic combination of either DRSP/EE (n=48) or CPA/EE (n=43) for 12 months. Basal serum total testosterone, free testosterone, androstenedione, dehydroepiandrosterone sulfate and SHBG levels, as well as Ferriman-Gallwey scores, were determined before and after treatment. Both COCs achieved a similar effect on clinical hirsutism scores, in addition to serum androgen and SHBG levels, after completion of therapy. The percentage reductions in total hirsutism score (median % (min-max)) during therapy were 0.70 (0-0.58) vs. 0.57 (0.10-1.00) at 6 months (p = 0.028) and 0.80 (0-0.42) vs. 0.81 (0-0.75) at 12 months (p = 0.6) in the DRSP/EE and CPA/EE groups, respectively. In conclusion, the DRSP/EE combination is at least as effective as the CPA/EE combination in improving hirsutism scores.



Indexes of Skin Care Research Abstracts
by Subject Category Most Recent


Google
 
Web SmartSkinCare.com

Home | About Us | Contact Us | Ask a Question | Resources

Copyright © 1999-2009 by Dr. G. Todorov / SmartSkinCare.com
Site Disclaimer | Copyright Certification

   
-- advertisements --